ABOUT THE DIABETIC COMPLICATIONS CONSORTIUM (DiaComp):
There is strong evidence that diabetic complications are linked via dysregulation of common pathways.
The NIDDK-sponsored Diabetic Complications Consortium (DiaComp) promotes communication and collaboration between research communities
investigating similar pathologic mechanisms in different organs by organizing an annual scientific meeting and
funding new research activities.
DiaComp Pilot and Feasibility Program
This program solicits and funds small Pilot and Feasibility (P&F) projects in high impact areas of complications research. Specifically, this
program aims to support discovery (hypothesis generating) and innovative (high risk/ high reward) research that is increasingly difficult to support
through standard NIH mechanisms. Basic, translational and clinical research proposals are encouraged. Research involving human subjects is limited to
observational studies with non-invasive or minimally invasive testing and must have IRB approval that includes the collection and use of human samples
for research purposes. Interventional clinical trials are beyond the scope of this program. Awards are expected to prepare the applicant(s) to submit a
future investigator initiated project (e.g. NIH R01). Lower priority will be given to applicants who have received DiaComp support in the past three years.
Applications of 5 pages
requesting up to $100,000 for one year
are due Friday, May 08, 2015.
Current areas of interest include, but are not limited to:
Interrogation of human samples or resources with genetics, epigenetics, and/or systems biology. Use of human tissue to identify different molecular
and anatomic “subtypes” of end-organ disease, including potential differences between T1D and T2D. Linking and coordination of human samples to
existing tissue repositories and databases.
Application of stem cells, including induced pluripotent stem (iPS) cells, and regenerative therapies to the repair and reversal of diabetic
complications. The development of stem cell based models of disease, including 3D tissue organoids.
Use of relevant model systems to accelerate gene X environment (GEI) studies. Pilot studies to assess the role of the microbiome or virome in diabetic
complications. Investigation of mechanisms for the possible role of metals in the development of complications and chelation therapy in the prevention or
reversal of complications.
Pilot studies to non-invasively image fibrosis, inflammation, or function of organs affected by diabetes.
Pilot studies to support the development and use of novel cell-based, organoid, or in vivo assays for the discovery and preclinical testing of potential
therapies for diabetic complications.
Budget requests should be commensurate with project needs over a one year project period. While average DiaComp P&F awards are
$60,000 Total Costs for one year, well justified requests for support of up to $100,000 Total Costs per
year will be considered.
International institutions and organizations are eligible for support.
Applications are due May 08, 2015
for September start dates.
For instructions on how to submit a Pilot & Feasibility Funding Program Application to the DiaComp
web portal please click the following link:
Funding Program Application Submission Basic Training (PDF)
Back to Top
Applicants may request up to $60,000 (direct + indirect costs) Total Costs for one year or well justified requests for support of up to $100,000. A
narrative justification should be provided only for any major equipment (cost greater than $5,000) deemed to be necessary for the proposed project.
The number of awards will depend upon the number, quality, duration, and cost of the applications received.
Awards will be made as subcontracts from the DiaComp Coordinating and Bioinformatics Unit (CBU) at the Georgia Regents University and not directly by the NIH.
Back to Top
Each application will receive a primary review by multiple external referees and be given scores for Significance,
Investigator, Innovation, Approach, Environment and an Overall Score. Scores will range from 1 to 9, where a score of
1 indicates an exceptionally strong application with essentially no weaknesses. A score of 9 indicates an application with
serious and substantive weaknesses with very few strengths; 5 is considered an average score. Please note that the Overall
Score is NOT an average of the other scores. The DiaComp External Evaluation Committee (EEC) will provide a secondary review
of all applications. Written comments will be provided for all reviewed applications. Scientists from the applicant
institution are in conflict and excluded from review. Final funding decisions will be made by the NIH.
Back to Top
RFA for DiaComp Pilot Projects is posted on DiaComp website, MMPC and other related websites, and notification of the postings is sent to
all US academic and research institutions.
|May 08, 2015
||Grants Submitted to CBU (Dr. Richard McIndoe, CA 4127, Georgia Regents University, Augusta, Georgia, 30912) |
||Projected start date for DiaComp Pilot Project Funding
Back to Top
The application is the standard PHS 398 form including face, abstract,
detailed budget, biographical and other support pages (up to 4 pages), and research plan. The research plan (Sections A-D are limited to 5 pages)
should include the following sections:
- Specific Aims,
- Background and Significance,
- Preliminary Studies,
- Research Design and Methods,
- Literature Cited,
- Vertebrate Animals
- Sharing Plan
submit an electronic version of the application via the DiaComp website (PDF format only please).
Eligible Project Directors/Principal Investigators:
Individuals with the skills, knowledge, and resources necessary to carry out the proposed research
are invited to work with their institution to develop an application for support. Individuals from
underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged
to apply for NIH support. New investigators are encouraged to apply, but they must have a full-time faculty
position or an equivalent position at non-academic institutions.
Public/State Controlled Institution of Higher Education; Private Institution of Higher Education;
Hispanic-serving Institution; Historically Black Colleges and Universities (HBCUs); Tribally Controlled
Colleges and Universities (TCCUs); Alaska Native and Native Hawaiian Serving Institutions; Nonprofit with
501(c)(3) IRS Status (Other than Institution of Higher Education); Nonprofit without 501(c)(3) IRS
Status (Other than Institution of Higher Education); Non-domestic (non-U.S.) Entity; Small Business;
For-Profit Organization (Other than Small Business); State Government; Regional Organization; U.S.
Territory or Possession; Indian/Native American Tribal Government (Federally Recognized); Indian/Native
American Tribal Government (Other than Federally Recognized); Indian/Native American Tribally Designated
Organization; Eligible agencies of the Federal government; Faith-based or community based organizations.
Back to Top
Please note that projects devoted to the development of new techniques and tests for the metabolic characterization of
mice are NOT responsive to this announcement and are better suited for the MMPC Pilot and Feasibility Grant Program
(please see www.mmpc.org for more details). In brief, this program supports applications to:|
- Develop new technologies or miniaturization of existing technologies for use in mice,
- Develop applications of existing technologies for use in mice,
- Provide new tests to meet identifiable, outstanding needs necessary to phenotype mouse models of metabolic disease, and
- Establish new types of mathematical models, informatics, databases or products that augment the mission of the center.
A summary of progress of funded projects is due two months following the completion
of the funding period.|
DiaComp awardees must follow NIH and HHS policies regarding the sharing of data and resources with the scientific community
(http://grants.nih.gov/grants/sharing.htm) and agree to submit to the
DiaComp web portal all data and resources resulting from the execution of the awarded application. Data and resources may
include, but are not limited to:
- histology images,
- experimental data,
- microarray data, and
- progress report(s).
All data and resources generated with DiaComp support will be made immediately available to "active" DiaComp awardees (see below) and publicly available
on the DiaComp website: (1) at the time of first publication, or (2) two years from the date of data upload to the
DiaComp website (www.diacomp.org). Under certain circumstances,
investigators may request an exception to the DiaComp two year public release policy by contacting NIH Program staff and requesting
a waiver. Such requests will be reviewed on a case-by-case basis and waivers will be granted only with sufficient and compelling prior justification.
DiaComp awardees are considered "active" and granted full access to the DiaComp website as members of the DiaComp "Steering Committee" for the duration of
their funding period plus 4 years. Outgoing awardees may request an extension from NIH Program staff beyond this "active" period.
Proprietary data and resources will be excluded from sharing consistent with NIH and HHS policies
Financial acknowledgment of award: Please acknowledge all posters, manuscripts or scientific materials that were generated in part or whole
using funds from the Diabetic Complications Consortium (DiaComp) using the following
text: 'Financial support for this work provided by the NIDDK Diabetic Complications Consortium (DiaComp,
www.diacomp.org), grant DK076169'.
For presentations and slides, please use the PowerPoint slide with the funding source logo found in the zip file here -
http://www.diacomp.org/images/diacomp-logos.zip - to indicate that DiaComp is a funding sources for your
Back to Top
Richard McIndoe, Ph.D. (Coordinator)
Coordinating and Bioinformatics Unit
Georgia Regents University
Center for Biotechnology and Genomic Medicine
1120 15th Street, CA4124
Augusta, GA 30912-4810
Back to Top